Travere Therapeutics Inc operates as a biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It focuses on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Market Cap | 1.506 Billion | Shares Outstanding | 61.226 Million | Avg 30-day Volume | 912.606 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.59 |
Price to Revenue | 8.1638 | Debt to Equity | 0.7745 | EBITDA | -121.667 Million |
Price to Book Value | 6.1474 | Operating Margin | -71.1086 | Enterprise Value | 1.538 Billion |
Current Ratio | 4.697 | EPS Growth | 0.154 | Quick Ratio | 4.584 |
1 Yr BETA | 1.0683 | 52-week High/Low | 31.65 / 12.75 | Profit Margin | -79.1644 |
Operating Cash Flow Growth | 65.3932 | Altman Z-Score | 1.2829 | Free Cash Flow to Firm | -14.084 Million |
Earnings Report | 2022-07-28 |
Please sign in first
none
9.2 Thousand total shares from 9 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
49,000 | 2022-05-11 | 1 | |
|
146,919 | 2022-05-11 | 5 | |
|
17,250 | 2022-05-11 | 3 | |
|
47,000 | 2022-05-11 | 1 | |
|
26,875 | 2022-05-11 | 1 | |
|
26,875 | 2022-05-11 | 1 | |
|
79,000 | 2022-05-11 | 1 | |
|
20,250 | 2022-05-11 | 1 | |
|
21,500 | 2022-05-11 | 1 | |
|
29,000 | 2022-05-11 | 1 | |
ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D |
|
43,672 | 2022-05-11 | 5 |
REED ELIZABETH E SVP, GC & CORPORATE SECRETARY |
|
41,838 | 2022-05-10 | 5 |
CLAGUE LAURA CHIEF FINANCIAL OFFICER |
|
35,655 | 2022-05-10 | 5 |
CALVIN SANDRA SVP, CHIEF ACCOUNTING OFFICER |
|
35,733 | 2022-05-10 | 4 |
DUBE ERIC M CHIEF EXECUTIVE OFFICER |
|
159,913 | 2022-02-10 | 6 |
HEERMA PETER CHIEF COMMERCIAL OFFICER |
|
124,497 | 2022-01-31 | 4 |
INRIG JULA CHIEF MEDICAL OFFICER |
|
8,000 | 2022-01-31 | 3 |
ROSENBERG NOAH L. CHIEF MEDICAL OFFICER |
|
47,614 | 2021-08-13 | 2 |
MCFARLANE NEIL F. CHIEF OPERATING OFFICER |
|
26,988 | 2019-05-15 | 0 |
|
29,000 | 2019-05-08 | 0 | |
SHIH ALVIN EVP OF RESEARCH & DEVELOPMENT |
|
158,334 | 2016-09-01 | 0 |
|
29,000 | 2016-05-18 | 0 | |
VALEUR JENSEN MARGARET E GENERAL COUNSEL |
|
100,000 | 2016-02-01 | 0 |
|
2,658,854 | 2015-01-13 | 0 | |
PLOTKIN HORACIO CHIEF MEDICAL OFFICER |
|
91,767 | 2014-12-12 | 0 |
|
129,165 | 2014-11-21 | 0 | |
|
No longer subject to file | 2014-11-14 | 0 | |
|
51,665 | 2014-08-14 | 0 | |
PANOFF MARC L CHIEF FINANCIAL OFFICER |
|
221,100 | 2014-02-24 | 0 |
|
2,097,671 | 2013-12-24 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-12 20:47:35 -0400 | 2022-05-12 | S | 1,050 | $21.51 | d | 41,838 | direct | yes | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||
2022-05-12 20:30:00 -0400 | 2022-05-11 | A | 3,000 | a | 17,875 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:49:57 -0400 | 2022-05-11 | S | 813 | $21.52 | d | 43,672 | direct | yes | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||
2022-05-12 20:33:39 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:18:15 -0400 | 2022-05-11 | A | 3,000 | a | 20,000 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:40:36 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:20:19 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:24:59 -0400 | 2022-05-11 | A | 3,000 | a | 40,000 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:45:55 -0400 | 2022-05-11 | S | 1,375 | $21.51 | d | 35,655 | direct | yes | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||
2022-05-12 20:26:35 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:49:57 -0400 | 2022-05-11 | S | 750 | $21.93 | d | 44,485 | direct | yes | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||
2022-05-12 20:33:39 -0400 | 2022-05-11 | A | 3,000 | a | 12,500 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:40:36 -0400 | 2022-05-11 | A | 3,000 | a | 17,875 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:20:19 -0400 | 2022-05-11 | A | 3,000 | a | 11,250 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:42:51 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:22:39 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:26:35 -0400 | 2022-05-11 | A | 3,000 | a | 70,000 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:30:00 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:35:33 -0400 | 2022-05-11 | S | 2,575 | $21.92 | d | 146,919 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | ||||
2022-05-12 20:18:15 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:42:51 -0400 | 2022-05-11 | A | 3,000 | a | 8,250 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:22:39 -0400 | 2022-05-11 | A | 3,000 | a | 38,000 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||||
2022-05-12 20:44:15 -0400 | 2022-05-11 | S | 445 | $21.92 | d | 35,733 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | ||||
2022-05-12 20:24:59 -0400 | 2022-05-11 | A | 9,000 | a | 9,000 | direct | ||||||||||
2022-05-12 20:44:15 -0400 | 2022-05-10 | S | 436 | $21.51 | d | 36,178 | direct | 6.1317 | 6.1317 | 2 | 0.0 | 1 | ||||
2022-05-12 20:45:55 -0400 | 2022-05-10 | S | 825 | $21.51 | d | 37,030 | direct | yes | 6.1317 | 6.1317 | 2 | 0.0 | 1 | |||
2022-05-12 20:47:35 -0400 | 2022-05-10 | S | 900 | $21.51 | d | 42,888 | direct | yes | 6.1317 | 6.1317 | 2 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 20:45:03 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 20:15:05 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 19:45:03 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 19:15:04 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 18:45:03 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 18:15:03 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 17:45:03 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 17:15:03 UTC | 0.5572 | 0.2628 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 16:45:04 UTC | 0.5557 | 0.2643 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 16:15:03 UTC | 0.5557 | 0.2643 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 15:45:03 UTC | 0.5557 | 0.2643 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 15:15:03 UTC | 0.5557 | 0.2643 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 14:45:03 UTC | 0.5153 | 0.3047 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 14:15:04 UTC | 0.5153 | 0.3047 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 13:45:03 UTC | 0.5153 | 0.3047 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 13:15:03 UTC | 0.5153 | 0.3047 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-20 12:45:03 UTC | 0.5153 | 0.3047 | 750000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-19 22:15:03 UTC | 0.5153 | 0.3047 | 700000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-19 21:45:08 UTC | 0.5153 | 0.3047 | 700000 |
TRAVERE THERAPEUTICS INC TVTX | 2022-05-19 21:15:03 UTC | 0.5153 | 0.3047 | 700000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND | TVTX | -22120.0 shares, $-686604.8 | 2021-12-31 | N-PORT |
AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund | TVTX | -12964.0 shares, $-402402.56 | 2021-12-31 | N-PORT |
Guidestone Funds- Strategic Alternatives Fund | TVTX | -6097.0 shares, $-189250.88 | 2021-12-31 | N-PORT |
Morningstar Funds Trust- Morningstar Alternatives Fund | TVTX | -10310.0 shares, $-283525.0 | 2022-01-31 | N-PORT |
Calamos Investment Trust/IL- Calamos Market Neutral Income Fund | TVTX | -63137.0 shares, $-1736267.5 | 2022-01-31 | N-PORT |